Anavex Life Sciences (AVXL) Competitors

Anavex Life Sciences (NASDAQ:AVXL) and Immatics (NASDAQ:IMTX) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, community ranking, earnings, profitability, institutional ownership, media sentiment, valuation and risk.

Which has preferable earnings & valuation, AVXL or IMTX?

Immatics has higher revenue and earnings than Anavex Life Sciences. Anavex Life Sciences is trading at a lower price-to-earnings ratio than Immatics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Anavex Life Sciences	N/A	N/A	-$47.98 million	-$0.68	-13.71
Immatics	$182.13 million	4.15	$39.53 million	-$1.06	-9.29

Do analysts rate AVXL or IMTX?

Anavex Life Sciences presently has a consensus target price of $42.60, indicating a potential upside of 357.08%. Immatics has a consensus target price of $19.75, indicating a potential upside of 100.51%. Given Anavex Life Sciences' higher possible upside, equities analysts clearly believe Anavex Life Sciences is more favorable than Immatics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Anavex Life Sciences	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.75
Immatics	0 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	3.00

Which has more volatility & risk, AVXL or IMTX?

Anavex Life Sciences has a beta of 0.75, suggesting that its share price is 25% less volatile than the S&P 500. Comparatively, Immatics has a beta of 0.44, suggesting that its share price is 56% less volatile than the S&P 500.

Is AVXL or IMTX more profitable?

Anavex Life Sciences has a net margin of 0.00% compared to Immatics' net margin of -85.93%. Anavex Life Sciences' return on equity of -36.78% beat Immatics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Anavex Life Sciences	N/A	-36.78%	-34.00%
Immatics	-85.93%	-41.31%	-17.89%

Do institutionals and insiders hold more shares of AVXL or IMTX?

31.2% of Anavex Life Sciences shares are held by institutional investors. Comparatively, 29.1% of Immatics shares are held by institutional investors. 11.6% of Anavex Life Sciences shares are held by company insiders. Comparatively, 3.3% of Immatics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Does the media refer more to AVXL or IMTX?

In the previous week, Immatics had 2 more articles in the media than Anavex Life Sciences. MarketBeat recorded 7 mentions for Immatics and 5 mentions for Anavex Life Sciences. Immatics' average media sentiment score of 0.82 beat Anavex Life Sciences' score of 0.45 indicating that Immatics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Anavex Life Sciences	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Immatics	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Does the MarketBeat Community favor AVXL or IMTX?

Anavex Life Sciences received 396 more outperform votes than Immatics when rated by MarketBeat users. Likewise, 74.20% of users gave Anavex Life Sciences an outperform vote while only 70.59% of users gave Immatics an outperform vote.

Company	Underperform	Outperform
Anavex Life Sciences	Outperform Votes 420 74.20%	Underperform Votes 146 25.80%
Immatics	Outperform Votes 24 70.59%	Underperform Votes 10 29.41%

Summary

Anavex Life Sciences beats Immatics on 9 of the 17 factors compared between the two stocks.